Compare BRKR & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRKR | PTCT |
|---|---|---|
| Founded | 1960 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.7B |
| IPO Year | 2000 | 2006 |
| Metric | BRKR | PTCT |
|---|---|---|
| Price | $58.65 | $73.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $48.54 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,895,600,000.00 | $264,734,000.00 |
| Revenue This Year | $6.30 | N/A |
| Revenue Next Year | $3.81 | $17.70 |
| P/E Ratio | $2,706.00 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $28.53 | $43.18 |
| 52 Week High | $56.22 | $87.50 |
| Indicator | BRKR | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 85.11 | 57.62 |
| Support Level | $46.84 | $69.81 |
| Resistance Level | N/A | $79.67 |
| Average True Range (ATR) | 2.19 | 2.40 |
| MACD | 1.32 | 0.07 |
| Stochastic Oscillator | 99.18 | 56.43 |
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.